Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Jazz Pharmaceuticals has announced that the US Patent and Trademark Office has issued a new US patent covering its once-a-day Luvox CR extended-release capsule product.
Subscribe to our email newsletter
The patent was assigned to Elan Pharma International and is exclusively licensed to Jazz Pharmaceuticals in the US through a product licensing agreement with Solvay Pharmaceuticals.
The patent claims the formulation incorporating Elan’s Sodas (Spheroidal Oral Drug Absorption System) technology, as well as a method of using the formulation for the treatment of obsessive compulsive disorder (OCD).
Luvox CR was previously approved by the FDA for the treatment of social anxiety disorder and OCD in adults. The patent has been listed for Luvox CR in the FDA Orange Book.